Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010 (2010), Article ID 848645, 11 pages
http://dx.doi.org/10.1155/2010/848645
Research Article

Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma

1Department of Dermatology, University of Regensburg, 93042 Regensburg, Germany
2Department of Hematology and Oncology, University of Regensburg, 93042 Regensburg, Germany
3Institute of Pathology, University of Regensburg, 93042 Regensburg, Germany
4Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
5Institute of Clinical Pathology, University of Erlangen, 91054 Erlangen, Germany
6OncoRay - Center for Radiation Research in Oncology, TU Dresden, 01307 Dresden, Germany
7Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland

Received 10 March 2009; Accepted 14 April 2009

Academic Editor: Dipak Panigrahy

Copyright © 2010 Stefanie Meyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Hla and K. Neilson, “Human cyclooxygenase-2 cDNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 16, pp. 7384–7388, 1992. View at Publisher · View at Google Scholar
  2. A. J. Dannenberg, N. K. Altorki, J. O. Boyle, D. T. Lin, and K. Subbaramaiah, “Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract,” Annals of the New York Academy of Sciences, vol. 952, pp. 109–115, 2001. View at Google Scholar
  3. M. J. Thun, S. J. Henley, and T. Gansler, “Inflammation and cancer: an epidemiological perspective,” Novartis Foundation Symposium, vol. 256, pp. 6–21, 2004. View at Google Scholar
  4. C. Bucher, P. Jordan, V. Nickeleit, J. Torhorst, and M. J. Mihatsch, “Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin,” Clinical Nephrology, vol. 51, no. 2, pp. 67–72, 1999. View at Google Scholar
  5. M. Oshima, N. Murai, S. Kargman et al., “Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor,” Cancer Research, vol. 61, no. 4, pp. 1733–1740, 2001. View at Google Scholar
  6. C. Denkert, M. Köbel, S. Berger et al., “Expression of cyclooxygenase 2 in human malignant melanoma,” Cancer Research, vol. 61, no. 1, pp. 303–308, 2001. View at Google Scholar
  7. C. Lee, J. A. Ramirez, J. Guitart, and L. K. Diaz, “Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression,” Journal of Cutaneous Pathology, vol. 35, no. 11, pp. 989–994, 2008. View at Publisher · View at Google Scholar
  8. S. Y. Buckman, A. Gresham, P. Hale et al., “COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer,” Carcinogenesis, vol. 19, no. 5, pp. 723–729, 1998. View at Google Scholar
  9. T. Nijsten, E. Geluyckens, C. Colpaert, and J. Lambert, “Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors,” Journal of Cutaneous Pathology, vol. 32, no. 5, pp. 340–347, 2005. View at Publisher · View at Google Scholar
  10. H. P. Koeffler, “Peroxisome proliferator-activated receptor gamma and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  11. E. Mueller, M. Smith, P. Sarraf et al., “Effects of ligand activation of peroxisome proliferator-activated receptor ? in human prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990–10995, 2000. View at Publisher · View at Google Scholar
  12. V. Subbarayan, A. L. Sabichi, J. Kim et al., “Differential peroxisome proliferator-activated receptor-? isoform expression and agonist effects in normal and malignant prostate cells,” Cancer Epidemiology, Biomarkers & Prevention, vol. 13, no. 11, pp. 1710–1716, 2004. View at Google Scholar
  13. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPAR?,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Publisher · View at Google Scholar
  14. G. Y. Zhang, N. Ahmed, C. Riley et al., “Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma,” British Journal of Cancer, vol. 92, no. 1, pp. 113–119, 2005. View at Publisher · View at Google Scholar
  15. S. Stadlmann, U. Gueth, E. Wight, L. A. Kunz-Schughart, A. Hartmann, and G. Singer, “Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma,” Journal of Clinical Pathology, vol. 60, no. 3, pp. 307–310, 2007. View at Publisher · View at Google Scholar
  16. S. Hazra, K. A. Peebles, S. Sharma, J. T. Mao, and S. M. Dubinett, “The role of PPARγ in the cyclooxygenase pathway in lung cancer,” PPAR Research, vol. 2008, Article ID 790568, 7 pages, 2008. View at Publisher · View at Google Scholar
  17. R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” Carcinogenesis, vol. 19, no. 1, pp. 49–53, 1998. View at Publisher · View at Google Scholar
  18. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar
  19. W. Placha, D. Gil, A. Dembinska-Kiec, and P. Laidler, “The effect of PPARγ ligands on the proliferation and apoptosis of human melanoma cells,” Melanoma Research, vol. 13, no. 5, pp. 447–456, 2003. View at Publisher · View at Google Scholar
  20. C. Freudlsperger, I. Moll, U. Schumacher, and A. Thies, “Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro,” Anti-Cancer Drugs, vol. 17, no. 3, pp. 325–332, 2006. View at Publisher · View at Google Scholar
  21. C. Hafner, A. Reichle, and T. Vogt, “New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy,” Current Cancer Drug Targets, vol. 5, no. 6, pp. 393–419, 2005. View at Publisher · View at Google Scholar
  22. A. Reichle, T. Vogt, B. Coras et al., “Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial,” Melanoma Research, vol. 17, no. 6, pp. 360–364, 2007. View at Publisher · View at Google Scholar
  23. A. Reichle, K. Bross, T. Vogt et al., “Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma,” Cancer, vol. 101, no. 10, pp. 2247–2256, 2004. View at Publisher · View at Google Scholar
  24. R. Simon, A. Nocito, T. Hübscher et al., “Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer,” Journal of the National Cancer Institute, vol. 93, no. 15, pp. 1141–1146, 2001. View at Publisher · View at Google Scholar
  25. L. Bubendorf, A. Nocito, H. Moch, and G. Sauter, “Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies,” The Journal of Pathology, vol. 195, no. 1, pp. 72–79, 2001. View at Publisher · View at Google Scholar
  26. P. J. Wild, S. Meyer, F. Bataille et al., “Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors,” Archives of Dermatology, vol. 142, no. 4, pp. 471–476, 2006. View at Publisher · View at Google Scholar
  27. A. Nocito, L. Bubendorf, E. M. Tinner et al., “Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade,” The Journal of Pathology, vol. 194, no. 3, pp. 349–357, 2001. View at Google Scholar
  28. D. Hanahan, G. Bergers, and E. Bergsland, “Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice,” The Journal of Clinical Investigation, vol. 105, no. 8, pp. 1045–1047, 2000. View at Publisher · View at Google Scholar
  29. V. Hofmeister, D. Schrama, and J. C. Becker, “Anti-cancer therapies targeting the tumor stroma,” Cancer Immunology, Immunotherapy, vol. 57, no. 1, pp. 1–17, 2008. View at Publisher · View at Google Scholar
  30. G. P. Vandoros, P. A. Konstantinopoulos, G. Sotiropoulou-Bonikou et al., “PPAR-gamma is expressed and NF-KB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 2, pp. 76–84, 2006. View at Publisher · View at Google Scholar
  31. H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cyclooxygenase-2 expression through PPARγ,” The Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000. View at Publisher · View at Google Scholar
  32. H. Ikawa, H. Kameda, H. Kamitani et al., “Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells,” Experimental Cell Research, vol. 267, no. 1, pp. 73–80, 2001. View at Google Scholar